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Impact of adult attention deficit hyperactivity disorder and
medication status on sleep/wake behavior and molecular
circadian rhythms
A. N. Coogan1, M. Schenk2, D. Palm2, A. Uzoni 2, J. Grube3, A. H. Tsang3, I. Kolbe3, N. M. McGowan1,4, R. Wandschneider2, M. Colla2,
H. Oster3, J. Thome2 and F. Faltraco2
Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatric condition that has been strongly associated with
changes in sleep and circadian rhythms. Circadian rhythms are near 24-h cycles that are primarily generated by an endogenous
circadian timekeeping system, encoded at the molecular level by a panel of clock genes. Stimulant and non-stimulant medication
used in the management of ADHD has been shown to potentially impact on circadian processes and their behavioral outputs. In
the current study, we have analyzed circadian rhythms in daily activity and sleep, and the circadian gene expression in a cohort of
healthy controls (N= 22), ADHD participants not using ADHD-medication (N= 17), and participants with ADHD and current use of
ADHD medication (N= 17). Rhythms of sleep/wake behavior were assessed via wrist-worn actigraphy, whilst rhythms of circadian
gene expression were assessed ex-vivo in primary human-derived dermal fibroblast cultures. Behavioral data indicate that patients
with ADHD using ADHD-medication have lower relative amplitudes of diurnal activity rhythms, lower sleep efficiency, more
nocturnal activity but not more nocturnal wakenings than both controls and ADHD participants without medication. At the
molecular level, there were alterations in the expression of PER2 and CRY1 between ADHD individuals with no medication
compared to medicated ADHD patients or controls, whilst CLOCK expression was altered in patients with ADHD and current
medication. Analysis of fibroblasts transfected with a BMAL1:luc reporter showed changes in the timing of the peak expression
across the three groups. Taken together, these data support the contention that both ADHD and medication status impact on
circadian processes.
Neuropsychopharmacology (2019) 44:1198–1206; https://doi.org/10.1038/s41386-019-0327-6
INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a common
neuropsychiatric condition, with prevalence in adults currently
estimated at ~5% worldwide [1], and a persistence rate from the
childhood condition in the order of 40–50% [2]. Aside from the
core symptoms of increased impulsivity, attentional difficulties,
and hyperactivity, sleep disturbances occur very frequently in
adult ADHD [3]. The nature of the relationship between ADHD and
sleep problems is not well understood, but in the general
population sleep disturbance can lead to inattention [4] and
impulsivity [5, 6], and as such disordered sleep may contribute to
symptom severity in ADHD. Further, stimulant and non-stimulant
medication used to manage ADHD in adults may themselves
adversely impact sleep [7].
Sleep is a complex physiological process, with a number of
definable stages that most likely serve a range of key functions
within the brain and the rest of the body [8]. A vital regulator of
sleep/wake behavior is the circadian clock [9]. The circadian
system’s interaction with the homeostatic drive to sleep in
determining the timing of sleep and wake behavior is articulated
in the two process model of sleep regulation [10]. The circadian
system is an endogenous network that imposes a daily temporal
architecture on physiology, and drives near 24-h rhythms in a host
of molecular, endocrine, neural, and behavioral outcomes [11]. The
molecular basis of the circadian clock is a panel of circadian clock
genes, which form transcriptional -translational feedback loops
regulating their own expression [12]. These clock genes also exert
a widespread influence on gene expression across the vast
majority of tissue and cell types, with 40% of all transcripts
showing rhythmic expression in at least one tissue in the mouse
[13]. Under normal circumstances, in order to maintain biological
salience the internal clock is synchronized (“entrained”) to
appropriate environmental time cues, the most important such
stimulus being light [14]. Altered entrainment of the circadian
clock has been described in a number of psychiatric conditions,
such as major depression and bipolar disorder [15]. Circadian
rhythms have previously been shown to be altered in adult ADHD
[16]. These alterations include dampening of rhythms of clock
gene expression [17], increased eveningness in ADHD [18], and
delayed dim-light melatonin onset [19].
Circadian changes associated with ADHD may be important in-
and-of-themselves through resultant changes in temporal
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patterns of cognitive and executive function (as many such
processes are under circadian control [20]). Further, circadian
changes may impact through dysfunction of the sleep/wake cycle,
with resulting daily impairments [8]. However, at present the
directionality of the relationships between the circadian clock,
sleep, and ADHD are unclear. For example, do altered circadian
rhythms lead to disturbed sleep and ADHD symptoms, or does
inattention/impulsivity/mind racing lead to sleep changes, which
in turn lead to circadian changes? These questions are further
complicated by the potential for ADHD medication, such as
methylphenidate and atomoxetine, to alter circadian processes
and sleep [21–24]. Indeed, sleep factors may moderate the clinical
impact of ADHD medication [25]. To start to address these
concerns, the current study examines circadian rhythms at the
behavioral and molecular levels in patients with ADHD who are
currently using ADHD medication, compared to healthy controls
and to patients with ADHD who are not using ADHD medication.
MATERIAL AND METHODS
Participant selection criteria
Ethical approval for the conduct of the study, including obtaining
skin samples and use of all human tissues, was given by the ethical
review committee of Rostock University (Registration-number:
A2013-159), and written informed consent was obtained from
each study participant. The study was conducted according to the
ethical guidelines of the Declaration of Helsinki.
Patients participating in the study were recruited via the Adult
ADHD Outpatient Clinic of the Department of Psychiatry, Rostock
University. All patients with ADHD were diagnosed by experienced
psychiatrists in advance. Patients were made aware of the study
through notices or by the study team directly contacting relevant
patients. The healthy control group was made up of acquain-
tances of people involved in the study, advertised by word of
mouth among employees of the clinic and employees of the Clinic
for Psychiatry and Psychotherapy, Rostock. Only adult individuals,
able to give informed consent, were included. Healthy controls
without a history of childhood and adult ADHD or other significant
diagnoses were matched for age and sex. Patients whose
symptoms of possible comorbidities were more impairing than
ADHD symptoms were excluded. Healthy controls were screened
for ADHD using the WURS-k and the ASRS V1.1 screener to
exclude subjects who showed evidence of ADHD in childhood or
adulthood. Shift workers were also excluded. Three participants
from the control group were ultimately excluded due to suspicion
of a sleep disorder from inspection of actigraphy data. For the
ADHD diagnosis, the WURS-k (Wender Utah Rating Scale) and the
IDA (Integrated Diagnosis of Adult ADHD) were used. The IDA is
composed of the ASRS V.1.1 (Adult ADHD Self Report Scale) and
self-assessment of symptoms according to DSM-IV and ICD-10
criteria. The IQ of the healthy controls and ADHD groups was
measured by using MWT-B (Multiple Selection Vocabulary Test).
Detailed information about the psychometry is given in the
Supplement. Details of the study sample can be found in Table 1
and Supplementary Table 1, 2 and 3.
Tissue isolation and fibroblast culture
Human dermal fibroblasts were isolated and cultured as described
by Takashima [26].
For additional information on study design and cell culture,
see Supplementary Material.
Actigraphy
In order to obtain objective measures of participants’ sleep and
circadian rhythm function, the rest–activity pattern of participants
was recorded using wrist-worn actigraphs (Actiwatch 2, Philips
Respironics, PA, USA). Actigraphs were worn on the non-dominant
wrist for a period of at least 7 consecutive days. The recording
interval of the device was set at 60-s epochs. Data occurring
before the first and after the final midnight of each record were
excluded, ensuring at least 6 complete days for each participant,
with a complete weekend included in each record. Estimates of
sleep/wake behavior were calculated using Actiware software
version 5.57 (Philips Respironics, as above). The default medium
activity threshold (40 activity counts) was selected for designating
sleep from wake states as this threshold accords well with
polysomnography and subjective sleep ratings [27].
Measurement of circadian gene expression
Upon confluency of the respective primary fibroblast cell culture
from each participant, seven culture flask replicates were prepared
and synchronized with 100 nm dexamethasone (Sigma-Aldrich,
Darmstadt, Germany) for 30min. Samples were harvested every
4 h starting with time 0 after dexamethasone synchronization, rinsed
with PBS (Gibco, Thermo Fisher, Paisley, UK), collected with solution
D (4.5 M guanidinium thiocyanate, 0.5% sodium-N-lauryl sarcosine,
25mM tri-sodium citrate, 0.1 M betamercaptoethanol) and frozen
at −70 °C. Later, total RNA was isolated by RNeasy Plus Mini Kit
(Qiagen, Hilden, Germany) and subjected to reverse transcription
with the use of Superscript III First-Strand Synthesis System
(Invitrogen, Darmstadt, Germany). Gene expression of CLOCK,
BMAL1, PER1, PER2, PER3, and CRY1 expression was measured by
real-time quantitative reverse transcriptase-polymerase chain reac-
tion (qRT-PCR) and analyzed for cycling behavior.
Viral infection, synchronization, and real-time bioluminescence
monitoring
Primary fibroblast cell cultures from healthy control samples (n=
7), ADHD patients currently using medication (n= 6) and ADHD
patients not using ADHD medication (n= 6) were trypsinized
(Gibco, Thermo Fisher, Paisley, UK), and 2.5 × 104 cells were
seeded to a 96-well culture plate containing culture medium as
Table 1. Clinical and demographic characteristics of the study sample
Controls ADHD without
medication
ADHD with
medication
n= 22 n= 17 n= 17
Age [years] 38.1 ± 12.2 37.1 ± 9.97 39.3 ± 10.9
Female 13 (52%) 7 (41.2%) 9 (52.9%)
Height [cm] 175.1 ± 8.2 172.6 ± 10.3 172.5 ± 7.1
Weight [kg] 77.4 ± 17.3 74.8 ± 11.91 73.9 ± 13.4
BMI 25.2 ± 4.37 25.06 ± 3.07 24.95 ± 4.83
Employed/retired 21/1 17/0 16/1
IQ 116 ± 13.4 107.8 ± 10.9 109.1 ± 13.0
WURSk score 12.3 ± 9.2 35.8 ± 10.6***,$ 46.4 ± 11.2***
ADHD score 5.3 ± 3.8 25.2 ± 4.8*** 26.12 ± 7.48***
MEQ 56.3 ± 11.1 43.3 ± 11.1** 49.3 ± 13.0
No psychiatric co-
morbidity
25 (100%) 8 (47%) 9 (53%)
Current
methylphenidate
usage
0 0 14 (83%)
Current atomoxetine
usage
0 0 4 (23%; N= 1
for MPH+ ATO
use)
ADHD subtype n/a 8 combined 16 combined
3 hyperactive 1 inattentive
6 inattentive
Further clinical information is detailed in Supplementary Table 1
**P < 0.01, ***P < 0.001 and $P < 0.05
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described above. Viral transduction was conducted on the next
day with ~1.68 × 108 infection units (IFUs) of a plasmid expressing
BMAL1:luc per dish in the presence of 8 µg/mL polybrene. The
BMAL1:luc lentiviral particles were produced from the
HEK293T cells as previously described [28]. One day after
transduction, cells were rinsed with PBS (Gibco, Thermo Fisher,
Paisley, UK) and refreshed with culture medium. After 2 days, the
cells were synchronized with 100 nm dexamethasone (Sigma
Aldrich, Darmstadt, Germany) for 2 h and the medium was
changed to DMEM without phenol red (Life Technologies,
Darmstadt, Germany) containing 10% fetal bovine serum, 25 mM
HEPES (Sigma Aldrich, Darmstadt, Germany), and 500 μM beetle
luciferin (Promega, Mannheim, Germany). Luminescence measure-
ments were performed with a Berthold TriStar LB 941. The
experiment was conducted for 7 days until rhythms dampened to
flatness. Details of the study sample can be found in Table 1 and
Supplementary Table 3.
Statistical methods
Circadian clock gene expression data were tested for significant
circadian rhythmicity, using CircWave v. 1.4 software (generated
by Dr. Roelof Hut; www.euclock.org) to determine the best-fitting
linear harmonic regression with an assumed period of 24-h and
with α set at 0.05. The center-of-gravity of each best-fitting
waveform in CircWave was used as the circadian acrophase, and
the associated estimation error was used as the SD. To obtain
circadian parameters including phase, period length, rhythm
amplitude, and damping rate, the LumiCycle Analysis program
(Actimetrics) and Actogram J software was used. Luminometry
data was detrended and smoothed with a rolling 3 h average as
previously described [29, 30]. Circadian parameters were derived
from cosinor analysis and period was determined from
Lomb–Scargle periodograms analysis.
Inferential statistics were carried out in either SPSS (IBM
Corporation) or JASP Stats (https://jasp-stats.org/). Actigraphic
data were analyzed via MANCOVAs, with age, sex and in some
cases ADHD symptom severity included in the model as co-
variates. For MANCOVAs, Pillai’s trace was used as the most robust
statistic in the presence of inequalities of group sizes. qRT-PCR
clock gene data were analyzed via mixed between-within
ANOVAs, with age and sex included as co-variates. Phase data
from both qRT-PCR and BMAL1:luc data were analyzed with
circular statistics in the Oriana Program (Kovach Computing
Services, UK). For all inferential tests, P < 0.05 was deemed to
indicate a statistically significant groupwise difference. For all
ANOVAs, effects sizes are indicated with partial ETA squared, and
interpreted according to Cohen [31]. Sample sizes were calculated
via GPower software; for multivariate analysis the assumptions
used were power of 0.8, α= 0.05 and 3 groups with 3 measures
and it being important to detect medium effect sizes (Cohen’s f2
of 0.15), returning a required total sample size of 51. For mixed
between-within ANOVA analysis of clock gene data, using similar
parameters for 3 groups and 7 within groups measurements
indicated a required total sample of 48.
RESULTS
Study sample
Table 1 and Supplementary Table 1, 2 and 3 describe the
composition of the study sample. There were no significant
differences in age, BMI, or sex across the three study groups, and
the two ADHD groups did not vary in clinical severity of ADHD
symptoms. MEQ scores indicated that un-medicated ADHD
patients displayed more evening preference than controls, but
ADHD patients with medication did not.
Actigraphy
Measures from the non-parametric circadian rhythm analysis were
analyzed across the three groups (controls, ADHD+medication,
ADHD no medication) to examine circadian rhythm timing and
robustness. Intradaily variability (IV), a measure of the within-day
consolidation of rest–activity patterns, inter-daily stability (IS), a
measure of variation in the activity rhythm across days, and
relative amplitude (RA), a measure of rhythm fragmentation were
assessed across the three groups in a MANCOVA, with age and sex
serving as co-variates (Fig. 1a). There was a statistically significant
Fig. 1 Actigraphic measures of circadian rhythm robustness (a) and timing (b) in healthy controls, ADHD+medication and ADHD with no
medication groups, displayed as boxplots and jittered data points. a There was no significant difference between groups for interdaily stability
(IS), but intradaily variability (IV) was significantly higher in controls than in the ADHD no medication group. Relative amplitude was
significantly lower in the ADHD+medication group than the control group. b There were no significant differences in the timing of
the activity rhythm, as assessed by the time-of-onset of the least active 5 h period (L5 onset), the time of mid-sleep on free days or social
jetlag. *P < 0.05, ***P < 0.001
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effect of group on these variables (Pillai’s trace= 0.263, F6,118=
3.16, P= 0.007, partial ETA squared= 0.147). When this effect was
probed further it was revealed that IS did not vary between
groups (P= 0.77), but IV (P= 0.026, partial ETA squared= 0.122)
and RA (P= 0.006, partial ETA squared= 0.166) did. Bonferroni
post-hoc tests showed that IV was lower in the ADHD+ no
medication group compared to healthy controls (P= 0.048), whilst
RA was significantly lower in the ADHD+medication group
compared to controls (P= 0.016). When ADHD symptom scores
were controlled for in comparisons between the two ADHD
groups, RA did vary according to medication status, with RA
weaker in the ADHD+medication group than the ADHD no
medication group (P= 0.008). These results indicate that the
ADHD+medication group had more rhythm fragmentation,
which was most likely due to the medication, whilst the ADHD
no medication group showed better rhythm consolidation (via IV)
than the control group. Next, actigraphic measures relating to
sleep timing were analyzed (time of the onset of L5, the least
active 5 h period, time of mid-sleep on weekend days, and social
jetlag, the difference between mid-sleep on weekdays and
weekend days; Fig. 1b). MANCOVA revealed no group-wise
difference in these dependent variables (Pillai’s trace= 0.058,
F6, 118= 0.59, P= 0.72).
Next, we examined activity during the sleep period. We
grouped sleep efficiency, L5 (the activity during the least active
5 h) and activity counts during sleep (Fig. 2a). MANCOVA showed a
significant effect of group (Pillai’s trace= 0.486, F6,118= 6.3, P <
0.001, partial ETA squared= 0.24), with effects on sleep efficiency
(P < 0.001 partial ETA squared= 0.37) and L5 (P= 0.008, partial
ETA squared= 0.15), and activity during sleep (P= 0.014, partial
ETA squared= 0.13). Sleep efficiency was lower in the ADHD+
medication group than controls (P < 0.001) or the ADHD no
medication group (P= 0.002 controlling for ADHD symptom
severity). L5 was higher in the ADHD+medication group than
the control group (P= 0.003) and the ADHD no medication group
(P= 0.029, controlling for ADHD symptom severity). Total activity
during sleep did not vary significantly between the two ADHD
groups (P= 0.38), but was significantly elevated in the ADHD+
meds group compared to control (P= 0.001). These results
indicate that the ADHD+medication group had a higher level
of activity during the night, and lower sleep efficiency than both
controls and ADHD patients without medication. Subsequently,
we examined parameters indicating the number of wakenings
during the sleep period: WASO (time spent in wakening after sleep
onset), number of wakenings, and the mean duration of
wakenings (Fig. 2b). MANCOVA showed a significant effect of
group on these dependent variables (Pillai’s trace= 0.436, F6,116=
5.47, P < 0.001, partial ETA squared= 0.218). There were group-
wise effects on WASO (P < 0.001, partial ETA squared= 0.39) and
average duration of wake bouts (P < 0.001, partial ETA squared=
0.39), but not on number of sleep bouts (P= 0.18). Post-hoc tests
showed that the ADHD+medication group had higher WASO
than controls (P < 0.001) and the ADHD+ no medication group
(P= 0.003, controlling for ADHD symptoms), and longer duration
wake bouts than controls (P < 0.001) or ADHD no medication (P=
0.005). These results appear to indicate that medicated ADHD
patients do not wake up more often during the night compared to
controls and ADHD patients without medication, but that when
they do they spend longer awake.
Ex-vivo clock gene expression in primary fibroblasts
The expression profiles of six clock genes were examined in
primary fibroblasts cultured from skin biopsies and synchronized
with dexamethasone (Fig. 3a). PER1 expression did not show a
significant ZT × group interaction via ANCOVA (controlling for sex
and age; Greenhouse–Geisser corrected F7.9,184= 1.98, P= 0.054).
PER2 expression did show a significant ZT × group interaction
(Greenhouse–Geisser corrected F4.4,102= 3.86, P= 0.019). Post-hoc
testing showed PER2 expression at ZT0 to be significantly higher
in the ADHD no medication group than controls (P= 0.004) and
the ADHD medication group (P= 0.030). PER3 expression was
strongly rhythmic in all three groups, but there was no ZT × group
interaction (Greenhouse–Geisser corrected F3.4,82, P= 0.57). There
was a significant ZT × group interaction term for CRY1 expression
(Greenhouse–Geisser corrected F4.9,113= 4.47, P= 0.001, partial
ETA squared= 0.16), with expression at ZT8 and ZT12 differing
between groups; the ADHD no medication group differed to the
control group (P= 0.010 and P= 0.013, respectively) and
the ADHD+medication group (correcting for ADHD symptom
severity, P= 0.021 and P= 0.009, respectively). There was no
Fig. 2 Actigraphic measures of sleep parameters, displayed as boxplots and jittered data points, across the three groups. a For measures of
activity during sleep, there was significantly lower sleep efficiency in the ADHD+medication group compared to either the control or the
ADHD no medication groups, and the ADHD+medication group had a greater amount of activity during L5 than the control group.
b Looking at wakening during the night in more detail, the ADHD+medication group had more time spent in wakening after sleep onset
(WASO), did not wake up more often, but when they did wake up the duration of the nocturnal wake bouts was longer. **P < 0.01, ***P < 0.001
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ZT × group interaction for BMAL1 expression (Greenhouse–Geisser
corrected F8.7,189= 1.26, P= 0.27). There was a significant ZT ×
group interaction for CLOCK expression (Greenhouse–Geisser
corrected F5.4,128= 3.2, P= 0.008), with expression significantly
lower in the ADHD+medication group at ZT0 than in the control
and ADHD no medication groups (P= 0.045 and P= 0.010,
respectively), lower in the ADHD+meds group than controls
(P= 0.006) and significantly higher at ZT24 in the ADHD+
medication group compared to controls (P= 0.035). When the
phase of expression of the clock genes was examined via cosinor
analysis to identify the center-of-gravity of the fitted wave, there
were no significant differences in the phase of PER1, PER2, PER3,
BMAL1, or CLOCK (Fig. 3b). There were significant differences in the
phase of CRY1 expression between the ADHD+medication and
the ADHD no medication groups (Watson–Williams F test, F1,27=
4.49, P= 0.038).
Next, we examined the expression of a BMAL1:luc reporter in
fibroblast cultures derived from control, ADHD+medication and
ADHD no medication groups (Fig. 4). There were no significant
differences in either the period or the amplitude of the
BMAL1:luc rhythm in these cultures following synchronization
(Fig. 4b; F2,13= 0.49, P= 0.64 for period and F2,13= 2.42, P= 0.10
for amplitude via ANCOVA with age and sex as covariates). When
the phase of the rhythm was examined, it was found that the peak
of expression on the 1st day after synchronization occurred later
in the ADHD no medication group compared to both the healthy
Fig. 3 Expression of clock genes in synchronized primary fibroblasts. a Expression profiles of PER1, PER2, PER3, CRY1, BMAL1, and CLOCK in
primary fibroblasts cultured from controls (unfilled circles), patients with ADHD+medication (black circles) and patients with ADHD no
medication (unfilled squares). ZT0 indicates time of culture synchronization. *P < 0.05, ***P < 0.001 for post-hoc pairwise test. b Rayleigh plots
of center-of-gravity for clock gene expression profiles derived from co-sinor fits. The diagonal line indicates mean center-of-gravity, and the
curved line indicates the 95% confidence interval
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controls and the ADHD+medication groups (P < 0.001 for both
via Watson–Williams F-test; Fig. 4c). On the 2nd day after
synchronization, the ADHD+medication group’s acrophase was
significantly later than both the control and ADHD no medication
groups (P < 0.001 and P < 0.01, respectively). On the 3rd day after
synchronization, there were no significant differences in the
acrophases between groups. These results indicate that the phase
of BMAL1:luc expression following a dexamethasone pulse appears
to be influenced by ADHD and medication status.
DISCUSSION
The results of the present study illustrate that both ADHD and
medication status impact on circadian function. We demonstrate
that ADHD medication status has a significant impact on a
number of behavioral circadian rhythms and sleep outcomes.
Clock gene expression data indicate an impact of both ADHD and
medication status on the core molecular clockworks. The ex-vivo
nature of the molecular assays used indicates that medication
status may elicit persistent changes in circadian function in ADHD
patients.
A number of previous studies have indicated that circadian
processes are altered in ADHD patients. For example, Baird et al.
[17] reported that adults with ADHD showed a blunting of
rhythms of PER2 and BMAL1 expression in oral mucosa, delayed
cortisol rhythms relative to wake-time, increased nocturnal
activity, and increased eveningness. However, this study did not
differentiate between medicated and un-medicated ADHD
patients. Van Veen et al. [19] reported phase-delay of the circadian
system in adult ADHD patients not using medication. The impact
of stimulants on sleep has previously been reported; for example,
a RCT in adults with ADHD showed that methylphenidate
treatment results in later bedtime and sleep onset, and shorter
but more consolidated sleep [32]. Further, preclinical studies
demonstrate that ADHD medication can impact on circadian
processes: Antle et al. [21] reported that chronic treatment of mice
with methylphenidate leads to a delay of sleep onset, a
lengthening of free-running circadian period and alters the
neuronal excitability of SCN neurons. These findings which are
consistent with the idea that methylphenidate may promote
sleep-onset insomnia. Methylphenidate has also been shown to
alter diurnal activity rhythms in rats [33]. A recent report in the
diurnal rodent Arvicanthis ansorgei also indicates that chronic
methylphenidate treatment leads to behavioral phase delays,
indicating that methylphenidate can impact on rhythms in both
nocturnal and diurnal rodents [24]. The non-stimulant atomox-
etine has been shown to induce phase-delays of free-running
rhythms in mice, as well as modulating photic-resetting of the
circadian clock [22]. Both methylphenidate and atomoxetine have
been shown to alter diurnal rhythms of clock gene expression
across a number of brain areas in mice [23]. Therefore, there is an
a-priori basis to believe that ADHD medication (either stimulant or
non-stimulant) may impact on circadian rhythm processes in
ADHD patients. Current findings from the actigraphic data indicate
that many of the observed differences may be due to medication
status, rather than ADHD per se. We observe a decrease of activity
rhythm fragmentation in ADHD patients using medication (as
measured by IV), a finding that has previously been reported [32].
Fig. 4 Expression of BMAL1:luc in fibroblasts from controls and ADHD patients. a Bioluminescence from the BMAL1:luc reporter in controls
(orange), ADHD+medication (green), and ADHD with no medication (blue). b Boxplots representing the rhythm amplitude and period of the
bioluminescence from BMAL1:luc transformed fibroblasts. There were no significant differences. c Rayleigh plots for the acrophases of
bioluminescence on each of the first 3 days following synchronization. ***P < 0.001, *P < 0.05. N= 7 for controls, N= 6 for both ADHD+
medication and ADHD no medication
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We also report a decrease in the rhythm amplitude, as assessed by
RA in patients with ADHD using medication compared to both
controls and un-medicated ADHD patients; therefore it may be
that medication is lowering rhythm amplitude by inducing
increased levels of nocturnal activity. This is supported by the
finding that L5 activity (typically from the 5 h period between near
midnight and near 5 a.m.) is increased in medicated ADHD
patients, compared to controls and un-medicated ADHD patients.
This increase in nocturnal activity likely results in the decrease in
sleep efficiency observed in medicated ADHD participants.
Medication is also associated with increased duration of average
nocturnal wake bouts, although not with more frequent wakening,
with the overall effect of greater time spent in wakening after
sleep onset. This finding is at variance from the findings of
Boonstra et al. [32], who reported decreases in both frequency and
duration of nocturnal wake bouts with methylphenidate treat-
ment. Differences in study design (e.g., RCT vs. observational
study) may account for such a discrepancy. It is noticeable that
neither ADHD or medication status differences were observed in
measures of rest–activity rhythm timing and social jetlag; previous
results also did not show changes in activity rhythm timing (e.g.,
measured by time of onset of L5 [17]), although phase markers
such as DLMO indicate a phase-delayed clock [19] and ADHD
patients show a marked shift towards in diurnal preference
towards eveningness (e.g., Rybak et al. [18]). As diurnal preference
may reflect both underlying phase of entrainment along with
psychological factors [16, 34], the observed shift to eveningness in
ADHD might primarily reflect an increased psychological pre-
ference rather than changes at the neurobiological or molecular
levels (although of course such systems may be recruited
indirectly to amplify such psychological changes).
Ex-vivo expression of clock genes in fibroblast has previously
been demonstrated to be a useful approach to the study of
circadian processes associated with sleep/wake behavior (e.g.,
[29, 35]) and psychiatric disorders (e.g., bipolar disorder [36] and
schizophrenia [37]). Ex-vivo fibroblasts have also been used in
other aspects of ADHD research [38]. An interesting facet of using
ex-vivo fibroblast cultures is that effects of current medication on
clock processes may not be acute, and may be more reflective of
long-lasting plastic changes possibly through epigenetic mod-
ifications [39, 40]. We report a number of changes in the rhythmic
expression of clock genes. Cultures from ADHD patients with no
medication showed higher expression of PER2 immediately after
synchronization than either controls or medicated ADHD cultures,
perhaps reflecting greater acute response to the dexamethasone
pulse in these cells. Expression of CLOCK was altered in the
ADHD+medication cultures at ZT0 and ZT24. The most striking
changes were in the expression of CRY1; cultures from un-
medicated ADHD patients showed delayed peak in expression.
Data from cell cultures transfected with the BMAL1:luc reporter
indicates that the rate of synchronization of BMAL1:luc rhythms
following a dexamethasone pulse varies across the three groups,
with cultures from ADHD patients with no medication seeming
to display an acrophase on day 1 in culture following the
synchronizing pulse that is similar to that on day 3, whilst both
controls and ADHD+medication cultures show an earlier peak on
day 1 which delays on subsequent days in culture. Data from the
BMAL:luc assay has greater temporal resolution and allows for
changes to be observed that might not be apparent from more
expression profiles from qRT-PCR samples taken every 4 h.
It is not clear why some components of the clock gene cycle
show differences in expression, and some do not; however, this
has previously been shown in fibroblasts from patients with
schizophrenia, where changes in mRNA cycling occur for PER2,
CRY1, and CLOCK [37]. These are the same genes that exhibit
differences in the current study. A previous study in adults with
ADHD demonstrated changes in PER2 and BMAl1 expression in the
oral mucosa [17]. It is interesting to note that a polymorphism in
CLOCK (3111T/C) that affects the expression of PER2 [41] has been
associated with ADHD and ADHD symptoms in a number of
studies [42–44]. Treatment status may also impact on clock gene
rhythms, as sub-chronic treatment with methylphenidate and
atomoxetine alters clock gene expression patterns in mice [23],
and psychostimulants in general are well described as altering
clock gene expression and circadian processes [45]. One
interpretation of the current data is that aspects of the molecular
clock systems are affected by ADHD status (at the gene expression
level at least; e.g., PER2 and CRY1 expression), and medication may
normalize these expression patterns, whilst also resulting in some
deviation in CLOCK expression. Some of these changes may be as
a result of altered synchronization within cultures following
dexamethasone pulses, as indicated by the BMAL1:luc data. Future
work may address the impact of such changes on rhythms of
global gene expression in ADHD via transcriptomic analysis, and
may also address whether changes in mRNA translate into
changes in clock gene protein product expression.
Overall, our data support the dual contention that both ADHD
status and ADHD medication impact on circadian processes and
sleep, highlighting the need to address both the effect of the
underlying condition and the ongoing management of the
condition on the circadian clock. There are a number of caveats
to consider in the interpretation of our results: the first is the
relatively modest sample size, and inherent heterogeneity within
the ADHD groups. Further, the subsample for the BMAL1::luc
analysis was smaller than for the Q-PCR analysis, although the
much greater temporal resolution of the bioluminescence
monitoring should result in an ability to detect more subtle
effects compared to static time-series sampling. Pharmacotherapy
regimes in the treated ADHD groups were not universal within the
group, with a small number of patients treated with atomoxetine;
however, we do believe that our sample was clinically represen-
tative. Notwithstanding these considerations, our data may have
clinical implications for how sleep disturbances in ADHD in adults
are considered and addressed: firstly, we highlight the key
importance of taking ADHD medication into account when
assessing sleep disturbances. Interestingly, chronotype has been
shown to moderate tolerability and side-effect profile on sleep
and mood of other psychoactive medications, such as levetir-
acetam in epilepsy, with morning types showing the lowest levels
of toleration [46]. The impact of methylphenidate or atomoxetine
on sleep may be moderated through chronotype, and future
studies should address this possibility. Second, the formulation
(extended vs. immediate release) and time of dosing may also
moderate the impact of ADHD medications on sleep and circadian
rhythms. A careful assessment of sleep patterns and chronotype of
patients before initiation of pharmacotherapy might be used to
inform time of optimal dosing for individuals. Finally, where sleep
disturbances persist in ADHD patients for whom it is otherwise
desirable to continue with pharmacotherapy, or indeed in those
patients not using ADHD medication but experiencing sleep
disturbances, consideration could be given to psychotherapeutic
and behavioral interventions to address sleep and circadian
disturbances. For example, pairing of cognitive behavioral therapy
for insomnia and/or light chronotherapy may be useful in
improving sleep outcomes, and possibly ADHD symptoms as in
general addressing sleep problems lead to primary symptom
improvement across a number of psychiatric conditions [47, 48].
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